Autolus Therapeutics (AUTL)
| Bid | 1.35 |
| Market Cap | 357.94M |
| Revenue (ttm) | 10.12M |
| Net Income (ttm) | -220.66M |
| EPS (ttm) | -0.86 |
| PE Ratio (ttm) | -1.56 |
| Forward PE | -1.94 |
| Analyst | Buy |
| Ask | 1.45 |
| Volume | 1,305,307 |
| Avg. Volume (20D) | 1,633,508 |
| Open | 1.42 |
| Previous Close | 1.41 |
| Day's Range | 1.33 - 1.43 |
| 52-Week Range | 1.10 - 5.00 |
| Beta | 2.06 |
About AUTL
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a program...
Analyst Forecast
According to 5 analyst ratings, the average rating for AUTL stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 643.49% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Autolus Therapeutics plc (AUTL) Q4 2024 Earnings Conference Call TranscriptAutolus Therapeutics plc (NASDAQ:AUTL ) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ET Company Participants Amanda Cray - IR Christian Itin - CEO Rob Dolski - CFO Conference Call Participa...
